使用后勤回归来比较疾病建模中的风险因素与不平衡的数据:维生素D和癌症发病率的案例研究
Mohammad Meysami1, Vijay Kumar1, McKayah Pugh2
1Department of Mathematics, Clarkson University, Potsdam, NY, United States.
Frontiers in oncology
|October 16, 2023
概括
这项研究引入了一种有效的低样本方法,以解决癌症预测模型中的不平衡数据. 这种新的方法提高了模型的性能,特别是使用维生素D数据预测癌症发病率.
科学领域:
- 统计 统计 统计 统计
- 生物统计学 生物统计学
- 医疗保健中的机器学习
背景情况:
- 在临床试验和疾病建模中,不平衡的数据很普遍,往往导致偏见的二元分类模型,有利于多数阶级.
- 现有的文献缺乏全面的方法来有效处理不平衡的数据,这影响了预测变量重要性的准确评估.
- 二元物流模型易受不平衡数据集的性能偏差的影响,阻碍了可靠的分析.
研究的目的:
- 解决临床试验分析中不平衡数据的二元物流模型的局限性.
- 提出并验证一种新的低样本方法,以提高对不平衡数据集的分类模型性能.
- 调查维生素D与不同亚群的癌症发病率之间的关系,考虑人口因素.
主要方法:
- 开发并应用了一种新的低样本技术,以解决二进制分类问题中的类不平衡问题.
- 拟议的方法在VITAL试验的公开数据上进行了测试,重点是癌症发病率预测.
- 在种族亚群中使用后勤回归来分析人口统计学因素 (BMI,年龄,性别) 对癌症发病率的影响,特别是检查维生素D的作用.
主要成果:
- 应用下样本方法导致模型性能在预测癌症发病率方面的显著改善.
- 民族亚群体内的分析揭示了人口因素对癌症发病率的影响,突出了维生素D的作用.
- 该研究证明了分类模型在理解不平衡数据的相对变量重要性方面的实用性.
结论:
- 开发的低样本方法有效地减轻了与癌症发病率预测中的不平衡数据相关的偏差.
- 这些发现强调了解决数据不平衡对于准确的临床试验分析和疾病建模的重要性.
- 这项研究为利用分类模型在不平衡数据集的情况下解释变量重要性提供了有价值的框架.
相关概念视频
01:25Statistical Methods for Analyzing Epidemiological Data
385
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
385
01:21Cancer Survival Analysis
359
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
359
01:20Comparing the Survival Analysis of Two or More Groups
202
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
202
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
01:29Bias in Epidemiological Studies
316
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
316
01:12Hazard Ratio
138
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
138